In Q42017, ISR surveyed 177 professionals from biopharmaceutical sponsors to ask about their companies’ current stances on selling and on manufacturing biosimilars. By looking at the differences in stances on selling versus manufacturing biosimilars, the data show there is some opportunity for CMOs to secure biosimilar manufacturing projects.
Continue at: https://www.bioprocessonline.com/doc/comparison-of-selling-vs-manufacturing-biosimilars-0001?vm_tId=2071573&user=e9e14da2-2932-478a-b692-b12fe9b1d5e5&utm_source=et_6212871&utm_medium=email&utm_campaign=BIO_06-27-2018&utm_term=e9e14da2-2932-478a-b692-b12fe9b1d5e5&utm_content=Comparison+Of+Selling+vs.+Manufacturing+Biosimilars
The text above is owned by the site above referred.
Here is only a small part of the article, for more please follow the link